Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T00:08:24.420Z Has data issue: false hasContentIssue false
  • English
  • Français

Radiotherapy dose and survival outcomes in human papillomavirus positive oropharyngeal cancer

Published online by Cambridge University Press:  18 June 2020

M Tam ,
S P Wu ,
N K Gerber ,
A Lee ,
D Schreiber ,
B Givi  and
K Hu
M Tam*
Affiliation:
Department of Radiation Oncology, New York University School of Medicine, USA
S P Wu
Affiliation:
Department of Radiation Oncology, New York University School of Medicine, USA
N K Gerber
Affiliation:
Department of Radiation Oncology, New York University School of Medicine, USA
A Lee
Affiliation:
Department of Radiation Oncology, State University of New York (‘SUNY’) Downstate Medical Center, New York, USA
D Schreiber
Affiliation:
Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA
B Givi
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, New York University School of Medicine, USA
K Hu
Affiliation:
Department of Radiation Oncology, New York University School of Medicine, USA
*
Author for correspondence: Dr Moses Tam, 160 E. 34th Street, New York, NY 10016, USA E-mail: [email protected] Fax: +1 212 731 5512
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

To evaluate the effect of definitive radiotherapy dose on survival in patients with human papillomavirus positive oropharyngeal carcinoma.

Methods

Human papillomavirus positive oropharyngeal carcinoma patients staged T1–3 and N0–2c, who received definitive radiotherapy (fraction sizes of 180 cGy to less than 220 cGy), were identified from the National Cancer Database 2010–2014 and stratified by radiation dose (50 Gy to less than 66 Gy, or 66 Gy or more).

Results

A total of 2173 patients were included, of whom 124 (6 per cent) received a radiation dose of 50 Gy to less than 66 Gy. With a median follow up of 33.8 months, patients had a 3-year overall survival rate of 88.6 per cent (95 per cent confidence interval = 87.1–90.1 per cent). On multivariate Cox analysis, a radiotherapy dose of 50 Gy to less than 66 Gy (hazard ratio = 0.95, 95 per cent confidence interval = 0.52–1.74, p = 0.86) was not a predictor of increased mortality risk.

Conclusion

Human papillomavirus positive oropharyngeal carcinoma patients had excellent outcomes with definitive radiotherapy doses of 50 Gy to less than 66 Gy. These results further support patients enrolling into clinical trials for radiation dose de-escalation.

Keywords

HPV, Human Papillomavirus VirusesOropharyngeal CancerNCDBNational Cancer DatabaseRadiotherapyDe-Escalation
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 134 , Issue 6 , June 2020 , pp. 533 - 540
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr M Tam takes responsibility for the integrity of the content of the paper

Portions of this work were presented in abstract and poster form at the 59th Annual Meeting of the American Society for Radiation Oncology, 24–27 September 2017, San Diego, California, USA.

References

Chaturvedi, AK, Engels, EA, Pfeiffer, RM, Hernandez, BY, Xiao, W, Kim, E et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–301CrossRefGoogle ScholarPubMed
Ang, KK, Harris, J, Wheeler, R, Weber, R, Rosenthal, DI, Nguyen-Tan, PF et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35CrossRefGoogle ScholarPubMed
Fakhry, C, Westra, WH, Li, S, Cmelak, A, Ridge, JA, Pinto, H et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261–9CrossRefGoogle Scholar
Lassen, P, Eriksen, JG, Hamilton-Dutoit, S, Tramm, T, Alsner, J, Overgaard, J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992–8CrossRefGoogle ScholarPubMed
Adelstein, DJ, Li, Y, Adams, GL, Wagner, H Jr, Kish, JA, Ensley, JF et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92–8CrossRefGoogle ScholarPubMed
Denis, F, Garaud, P, Bardet, E, Alfonsi, M, Sire, C, Germain, T et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69–76CrossRefGoogle ScholarPubMed
Machtay, M, Moughan, J, Trotti, A, Garden, AS, Weber, RS, Cooper, JS et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582–9CrossRefGoogle ScholarPubMed
Chera, BS, Amdur, RJ, Tepper, J, Qaqish, B, Green, R, Aumer, SL et al. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2015;93:976–85CrossRefGoogle ScholarPubMed
Marur, S, Li, S, Cmelak, AJ, Gillison, ML, Zhao, WJ, Ferris, RL et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx – ECOG-ACRIN Cancer Research Group. J Clin Oncol 2017;35:490–7CrossRefGoogle ScholarPubMed
Chen, AM, Felix, C, Wang, PC, Hsu, S, Basehart, V, Garst, J et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol 2017;18:803–11CrossRefGoogle ScholarPubMed
Winchester, DP, Stewart, AK, Phillips, JL, Ward, EE. The National Cancer Data Base: past, present, and future. Ann Surg Oncol 2010;17:4–7CrossRefGoogle ScholarPubMed
Eisbruch, A, Harris, J, Garden, AS, Chao, CK, Straube, W, Harari, PM et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2010;76:1333–8CrossRefGoogle Scholar
Quon, H, Vapiwala, N, Forastiere, A, Kennedy, EB, Adelstein, DJ, Boykin, H et al. Radiation therapy for oropharyngeal squamous cell carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol 2017;35:4078–90CrossRefGoogle Scholar
Sher, DJ, Adelstein, DJ, Bajaj, GK, Brizel, DM, Cohen, EEW, Halthore, A et al. Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2017;7:246–53CrossRefGoogle ScholarPubMed
O'Sullivan, B, Huang, SH, Su, J, Garden, AS, Sturgis, EM, Dahlstrom, K et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016;17:440–51CrossRefGoogle ScholarPubMed
Chen, AM, Li, J, Beckett, LA, Zhara, T, Farwell, G, Lau, DH et al. Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer. Laryngoscope 2013;123:152–7CrossRefGoogle ScholarPubMed
Hampson, L, El Hady, ES, Moore, JV, Kitchener, H, Hampson, IN. The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. FASEB J 2001;15:1445–7CrossRefGoogle ScholarPubMed
Zheng, Y, Zhang, J, Rao, Z. Ribozyme targeting HPV16 E6E7 transcripts in cervical cancer cells suppresses cell growth and sensitizes cells to chemotherapy and radiotherapy. Cancer Biol Ther 2004;3:1129–34CrossRefGoogle ScholarPubMed
Spanos, WC, Nowicki, P, Lee, DW, Hoover, A, Hostager, B, Gupta, A et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135:1137–46CrossRefGoogle ScholarPubMed
Williams, R, Lee, DW, Elzey, BD, Anderson, ME, Hostager, BS, Lee, JH. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 2009;31:911–18CrossRefGoogle ScholarPubMed
Tam, M, Hu, K. Regional radiation therapy for oropharyngeal cancer in the HPV era. Semin Radiat Oncol 2019;29:126–36CrossRefGoogle ScholarPubMed
Riaz, N, Sherman, EJ, Katabi, N, Leeman, JE, Higginson, DS, Boyle, J et al. . A personalized approach using hypoxia resolution to guide curative-intent radiation dose-reduction to 30 Gy: a novel de-escalation paradigm for HPV-associated oropharynx cancers (OPC). J Clin Oncol 2017;35(15 suppl):6076CrossRefGoogle Scholar
Feng, FY, Kim, HM, Lyden, TH, Haxer, MJ, Worden, FP, Feng, M et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010;28:2732–8CrossRefGoogle ScholarPubMed
Fakhry, C, Zhang, Q, Nguyen-Tan, PF, Rosenthal, D, El-Naggar, A, Garden, AS et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365–73CrossRefGoogle ScholarPubMed
Gillison, ML, Trotti, AM, Harris, J, Eisbruch, A, Harari, PM, Adelstein, DJ et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019;393:40–50CrossRefGoogle ScholarPubMed